Medium materiality6/10
Mizuho raises ADMA Biologics target to $18
Why it may matterVerify against the original reporting
The target implies sizable upside, but this is an analyst estimate without supporting details, so confidence is limited.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Mizuho raised its ADMA price target to $18, about 72% above the posted price of $10.48. No rationale for the revision is provided.
- Target: $18; posted price: $10.48.
- Mizuho analyst: Anthony Petrone.
Key facts
- 01
Target: $18
- 02
Posted price: $10.48
- 03
Analyst firm: Mizuho Securities
- 04
Analyst: Anthony Petrone
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.